Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund have collaborated with global life science company Evotec SE to establish 65LAB, a pioneering initiative aimed at advancing drug discovery and nurturing new therapeutics companies in Singapore. This unique partnership seeks to harness the global capabilities of its members to expedite the commercialization of promising research from prestigious academic and R&D institutions in Singapore, including A*STAR, NUS, and Duke-NUS Medical School. Over an 18-24 month period, 65LAB will invest up to $1.5 million in selected academic projects, providing scientists with access to Evotec's resources and expertise in developing innovative therapies. The initiative aims to create long-term partnerships, support the growth of Singapore's biotech ecosystem, and develop therapies with a global health impact.

 

Read More - https://www.techdogs.com/tech-news/pr-newswire/65lab-launches-in-partnership-with-evotec-se-and-backed-by-leading-global-investors-to-advance-drug-discovery-and-new-company-creation-in-singapore